Intelligence Feed event · Policy · 2026-09-12

    FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy

    Question

    FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy

    Direct answer

    The U.S. Food and Drug Administration approved Scholar Rock's Isembyld (apitegromab-mstn) for spinal muscular atrophy. The drug is designed to work in combination with existing SMN treatments, supported by clinical endpoints in the Phase 3 SAPPHIRE study demonstrating motor function gains.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/fda-approves-scholar-rock-s-isembyld-as-first-muscle-targeted-sma-therapy-d149dc

    POLICY
    FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
    The U.S. Food and Drug Administration approved Scholar Rock's Isembyld (apitegromab-mstn) for spinal muscular atrophy. The drug is designed to work in combination with existing SMN treatments, supported by clinical endpoints in the Phase 3 SAPPHIRE study demonstrating motor function gains.
    SRRK
    Impact
    73
    SEP 12
    SIG
    95%
    SRRK
    FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
    The U.S. Food and Drug Administration approved Scholar Rock's Isembyld (apitegromab-mstn) for spinal muscular atrophy. The drug is designed to work in combination with existing SMN treatments, supported by clinical endpoints in the Phase 3 SAPPHIRE study demonstrating motor function gains.
    → FDA approval of Isembyld provides Scholar Rock (SRRK) with its first commercial product launch in spinal muscular atrophy alongside existing SMN-targeted therapies.
    Impact
    The U.S. Food and Drug Administration approved Scholar Rock's Isembyld (apitegromab-mstn) for spinal muscular atrophy. The drug is designed to work in combination with existing SMN treatments, supported by clinical endpoints in the Phase 3 SAPPHIRE study demonstrating motor function gains.
    Affected
    SRRK
    Transmission
    FDA approval of Isembyld provides Scholar Rock (SRRK) with its first commercial product launch in spinal muscular atrophy alongside existing SMN-targeted therapies.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SRRKregulatory drug approval commercialization milestoneUp1-5dFDA approved lead therapy Isembyld based on Phase 3 SAPPHIRE data.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month